Today’s patients want and deserve a more efficient and high-tech experience and the next generation of providers are no different. These upgrades can improve our productivity and enhance the quality of our patients’ lives. The post Disrupting Legacy Systems: Preparing for the Next Generation of Health Tech appeared first on MedCity News.
This disconnect has become one of the defining operational challenges facing Medicaid plans. What was once considered an under-the-radar risk is no longer subtle. It is now actively shaping plan performance, provider behavior, and financial outcomes across Medicaid systems. The post HR1 Is Stress Testing Medicaid Performance Metrics and Exposing a Failure in Engagement appeared…
Health tech companies made several major funding announcements in January. Here is a list of some of the biggest funding rounds. The post 4 Notable Health Tech Funding Announcements in January appeared first on MedCity News.
In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid-19, the FDA said its policy will compel generation of more evidence for these groups. Our roundup of regulatory news includes notable firsts for Alzheimer’s diagnosis and migraine treatment. The post New FDA…
Some large health systems are experimenting with selling their internal capabilities — such as IT support, revenue cycle management and call center operations — to smaller hospitals as a new revenue stream. While the approach is still rare, it has the potential to help health systems monetize their expertise and infrastructure, one healthcare consultant said….
Nextech CEO Rusty Frantz details the launch of Cora Scribe with an early focus on ophthalmology
Healthcare association leaders and senators reacted to the dramatic developments at the CDC
Evommune’s EVO301 met the goals of a placebo-controlled Phase 2a study in atopic dermatitis. The biologic drug neutralizes a signaling protein involved in multiple inflammatory pathways, which could differentiate it from the blockbuster Sanofi and Regeneron Pharmaceuticals immunology drug Dupixent. The post Evommune Starts Making Case to Challenge Dominance of Sanofi’s Dupixent in Atopic Dermatitis…
This brief reviews the latest data on the 988 LGBTQI+ service and explores its future, including recent uncertainties.